AVBP vs AVIR

ArriVent BioPharma, Inc. vs Atea Pharmaceuticals, Inc. — Valuation Comparison 2026

AVBP

Biotechnology
ArriVent BioPharma, Inc.
Quality
3.6
out of 10
Value Trap
12
SAFE
Price
$26.97
Last close
Models
7/13
Active
VS

AVIR

Biotechnology
Atea Pharmaceuticals, Inc.
Quality
4.2
out of 10
Value Trap
18
SAFE
Price
$4.73
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType AVBP Fair ValueAVBP Upside AVIR Fair ValueAVIR Upside
Bayesian DCF Intrinsic $7.90 -70.7% $1.47 -68.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.59 -98.0% $0.59 -89.4%
Dynamic NAV Asset-Based $6.38 -76.3% $3.52 -25.6%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for AVBP vs AVIR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

AVBP vs AVIR — Which Stock Is More Undervalued?

AVIR scores higher with a 4.2/10 quality rating vs AVBP's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing ArriVent BioPharma, Inc. (AVBP) and Atea Pharmaceuticals, Inc. (AVIR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

AVBP currently trades at $26.97 with a QOC of 3.6/10, while AVIR trades at $4.73 with a QOC of 4.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).